Cyclometalating Ligand Affords NIR Absorption in Ruthenium Complexes for Type‐I Photodynamic Therapy
Angewandte Chemie International Edition · 2025
DOI: 10.1002/anie.202512296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2025. Verfasst von Zongwei Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Fine Chemicals, Frontiers Science Center for Smart Materials Oriented Chemical Engineering, Dalian University of Technology, …. Hauptthemen laut MEDLINE: Photochemotherapy, Ruthenium, Photosensitizing Agents, Coordination Complexes. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Science Foundation of China, Key R&D Program of Liaoning Province, Xingliao Talent Program for Young Top Talents.
Abstract (Originalsprache)
The development of NIR photosensitizers (PSs) based on Ru complexes with Type‐I process holds substantial promise for photodynamic therapy (PDT) of cancer, though this breakthrough remains unrealized to date. Herein, a pair of cyclometalated Ru enantiomers, [Λ/Δ‐Ru‐dqpy‐TPABP]Cl (dqpy: 2,6‐di(quinolin‐2‐yl)pyridine; TPABP: 4‐(4‐(pyridine‐2‐yl)‐2,1,3‐benzothiadiazol‐7‐yl)triphenylamine) (Λ/Δ‐Ru‐TPABP), were synthesized and evaluated. These complexes exhibit strong Ru(d) and TPABP(π) → dqpy(π*) charge transfer ((metal and ligand)–ligand charge transfer; ML–LCT) absorption at ∼640 nm, with an extended absorption tail reaching up to 800 nm. Moreover, the TPABP ligand, with its strong electron‐rich capacity, contributes to T 1 formation, which increases the electron transfer possibility in the triplet state and promotes Type‐I PDT, making it highly effective for killing cancer cells under hypoxic conditions. Further encapsulating Λ/Δ‐Ru‐TPABP into polymeric nanoparticles results in high tumor inhibition efficiency (>85%) and causes a strong tumoricidal effect and inhibits lung metastasis of breast tumors under 700 nm light irradiation, thus offering a new strategy for developing NIR Ru complexes for anticancer treatment through the design of cyclometalating ligand.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Fine Chemicals, Frontiers Science Center for Smart Materials Oriented Chemical Engineering, Dalian University of Technology, Dalian, 116024, China.
- DWI-Leibniz Institute for Interactive Materials & Institute of Technical and Macromolecular Chemistry, RWTH Aachen University, 52074, Aachen, Germany.
- Ningbo Institute of Dalian University of Technology, Ningbo, 315016, China.
- Liaoning Binhai Laboratory, Dalian, 116023, China.
ORCID-Profile: Wen Sun
Förderung
- National Science Foundation of China
- Key R&D Program of Liaoning Province
- Xingliao Talent Program for Young Top Talents
- Postdoctoral Fellowship Program of CPSF
- China Postdoctoral Science Foundation
- Liaoning Binhai Laboratory
- "Oncology +" Open Project of Liaoning Cancer Hospital
- Fundamental Research Fundamental Funds for the Central Universities
Zitieren
APA
Zhang, Z., Zeng, X., Zhou, X., Ma, Z., He, M., Zhou, D., Long, S., Fan, J., Peng, X., & Sun, W. (2025). Cyclometalating Ligand Affords NIR Absorption in Ruthenium Complexes for Type‐I Photodynamic Therapy. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202512296
Vancouver
Zhang Z, Zeng X, Zhou X, Ma Z, He M, Zhou D, et al. Cyclometalating Ligand Affords NIR Absorption in Ruthenium Complexes for Type‐I Photodynamic Therapy. Angewandte Chemie International Edition. 2025. doi:10.1002/anie.202512296
BibTeX
@article{Zhang2025,
author = {Zhang, Zongwei and Zeng, Xiaolong and Zhou, Xiao and Ma, Zhiyuan and He, Maomao and Zhou, Danhong and Long, Saran and Fan, Jiangli and Peng, Xiaojun and Sun, Wen},
title = {Cyclometalating Ligand Affords NIR Absorption in Ruthenium Complexes for Type‐I Photodynamic Therapy},
journal = {Angewandte Chemie International Edition},
year = {2025},
doi = {10.1002/anie.202512296}
}
EUVIMED